Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results.
Matthias AugustinEsteban DaudénUlrich MrowietzMaria-Polina KonstantinouS GerdesK KingoJacek Cezary SzepietowskiJ L PerrotA CucciaM RisslerS GathmannC SiederR OrsenigoP JagielloT BachhuberPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2020)
Secukinumab treatment resulted in complete normalization of QoL in a substantial proportion of psoriasis patients, and their families, regardless of their prior treatment history.